title: Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers.
authors.affiliation: Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
authors.forename: R
authors.initials: R
authors.lastname: Stupp
authors.forename: A F
authors.initials: AF
authors.lastname: Hottinger
authors.forename: M J
authors.initials: MJ
authors.lastname: van den Bent
authors.forename: P-Y
authors.initials: PY
authors.lastname: Dietrich
authors.forename: A A
authors.initials: AA
authors.lastname: Brandes
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D005909:Glioblastoma / Q000188:drug therapy / Q000532:radiotherapy; D005910:Glioma / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide